Care for diabetic patients with vascular disease

Česká verzia

Authors: A. Šmahelová
Authors place of work: Diabetologické centrum Kliniky gerontologické a metabolické Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MU Dr. Luboš Sobotka, CSc.
Published in the journal: Vnitř Lék 2010; 56(4): 324-328
Category: 11th National Diabetes Symposium "Diabetes and Angiology", Hradec Kralove, 5 to 6 June 2009

Summary

There is an association between vascular complications and diabetes compensation in ambulatory as well as inpatient care. Diagnostics of vascular complications in diabetic patients are linked to increased risk of contrast‑induced nephropathy. Treatment of severe vascular complications usually requires hospitalization. Achieving and maintaining target glycaemia is essential. Compensation of hyperglycaemia must be sufficient and timely; the risk of hypoglycaemia must not be ignored. Target glycaemia values must be adjusted individually, insulin administration is usually preferred.

Key words:
complications of diabetes – comorbidities of diabetes – contrast‑induced nephropathy – target glycaemia – cardiovascular risk – diabetes mellitus

Zdroje

1. ÚZIS ČR, Aktuální informace č. 36, 2009.

2. Horák P. Farmakoekonomika léčby diabetu – trendy u nás. Vnitř Lék 2009; 55, 331– 342.3. Almeda‑ Valdes P, Cuevas‑ Ramos D, Mehta R et al. UKPDS Risk Engine, Decode and Diabetes PHD Models for the Estimation of Cardiovascular Risk in Patients with Diabetes. Curr Diabetes Rev 2009. Epub ahead of print.

4. Holman RR, Watkins PJ. UKPDS – the first 30 years. Oxford: Wiley‑ Blackwell 2008.

5. Kauffman AB, Delate T, Olson KL et al. Relationship between haemoglobin A1C values and recurrent cardiac events: A retrospective, longitudinal cohort study. Clin Drug Investig 2008; 28: 501– 507.

6. Schwab SJ, Hlatky MA, Pieper KS et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989; 320: 149– 153.

7. Asif A, Epstein M. Prevention of radiocontrast‑induced nephropathy. Am J Kidney Dis 2004; 44: 12– 24.

8. Schweiger MJ, Chambers CE, Davidson CJ et al. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv 2007; 69: 135– 140.

9. Rudnick M, Feldman H. Contrast‑induced nephropathy: what are the true clinical consequences? Clin J Am Soc Nephrol 2008; 3: 263– 272.

10. Gruberg L, Mintz GS, Mehran R et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre‑existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36: 1542– 1548.

11. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259– 2264.

12. Dussol B, Morange S, Loundoun A et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 2006; 21: 2120– 2126.

13. Calabrese AT, Coley KC, DaPos SV et al. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002; 162: 434– 437.

14. Holstein A, Stumvoll M. Contraindications can damage your health – is metformin a case in point? Diabetologia 2005; 48: 2454– 2459.

15. Briguori C, Airoldi F, D’Andrea D et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007; 115: 1211– 1217.

16. Šmahelová A. Konzervativní léčba diabetické mikroangiopatie a makroangiopatie. Čas Lék Čes 2009; 148: 72– 79.

17. NovoNordisk Book if Abstracts, Internatiional Diabetes Federation 20th World Diabetes Congress, Montreal, 18.– 22. October 2009.

18. ZS/ 1a/ 10 Postupy pro diagnostiku a terapii vybraných stavů závazné pro zdravotnická pracoviště FN HK A ZS/ 4- PPZ/ 10.

19. Finfer S, Chittock DR, Su SY et al. NICE SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283– 1297.

20. Clement S, Braithwaite SS, Magee MF et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27: 553– 591.

21. Fonseca VA. Clinical Diabetes: translating Research into Practice. 1st ed. Philadelphia: Saunders Elsevier 2006.22. Malmberg K, Norhammar A, Wedel H et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long‑term results from the Diabetes and Insulin‑Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99: 2626– 2632.

23. van den Berghe G, Wouters P, Weekers Fet al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359– 1867.

24. Malmberg K, Rydén L, Wedel H et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity Eur Heart J 2004; 26: 650– 661.

25. van den Berghe G. Insulin vs. strict blood glucose control to achieve a survival benefit after AMI? Eur Heart J 2005; 26: 639– 641.

26. Hirsch IB. Were We Wrong About Insulin and Acute Myocardial Infarction? DOC News. 2004. Available from: http:/ / docnews.diabetesjournals.org/ content/ 1/ 2/ 4.full.

27. Wei M, Gibbons LW, Mitchell TL et al. Low fasting plasma glucose level as a predictor of cardiovascular disease and all‑cause mortality. Circulation 2000; 101: 2047– 2052.28. Whitmer RA, Gunderson EP. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. JAMA 2009; 301: 1565– 1572.

29. Gill GV, Woodward A, Casson IF et al. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes – the “dead in bed” syndrome revisited. Diabetologia 2009; 52: 42– 45.

30. Tu E, Twigg SM, Semsarian C. Sudden death in type 1 diabetes: the mystery of the ‚dead in bed‘ syndrome. Int J Cardiol 2010; 138: 91– 93.